ATE373016T1 - Induktion von immunologischer toleranz gegen einen therapeutischen antikörper durch varianten des therapeutischen antikörpers - Google Patents

Induktion von immunologischer toleranz gegen einen therapeutischen antikörper durch varianten des therapeutischen antikörpers

Info

Publication number
ATE373016T1
ATE373016T1 AT97905226T AT97905226T ATE373016T1 AT E373016 T1 ATE373016 T1 AT E373016T1 AT 97905226 T AT97905226 T AT 97905226T AT 97905226 T AT97905226 T AT 97905226T AT E373016 T1 ATE373016 T1 AT E373016T1
Authority
AT
Austria
Prior art keywords
therapeutic antibody
antibody
immunological tolerance
variants
induction
Prior art date
Application number
AT97905226T
Other languages
German (de)
English (en)
Inventor
Herman Waldmann
Lisa Gilliland
Masahide Tone
Mark Frewin
Louise Walsh
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of ATE373016T1 publication Critical patent/ATE373016T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97905226T 1996-02-20 1997-02-20 Induktion von immunologischer toleranz gegen einen therapeutischen antikörper durch varianten des therapeutischen antikörpers ATE373016T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9603507.6A GB9603507D0 (en) 1996-02-20 1996-02-20 Antibody variants

Publications (1)

Publication Number Publication Date
ATE373016T1 true ATE373016T1 (de) 2007-09-15

Family

ID=10789047

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97905226T ATE373016T1 (de) 1996-02-20 1997-02-20 Induktion von immunologischer toleranz gegen einen therapeutischen antikörper durch varianten des therapeutischen antikörpers

Country Status (11)

Country Link
US (2) US20020048578A1 (cg-RX-API-DMAC7.html)
EP (1) EP0970127B1 (cg-RX-API-DMAC7.html)
JP (1) JP4574750B2 (cg-RX-API-DMAC7.html)
AT (1) ATE373016T1 (cg-RX-API-DMAC7.html)
AU (1) AU723366B2 (cg-RX-API-DMAC7.html)
CA (1) CA2246715C (cg-RX-API-DMAC7.html)
DE (1) DE69738138T2 (cg-RX-API-DMAC7.html)
ES (1) ES2294793T3 (cg-RX-API-DMAC7.html)
GB (1) GB9603507D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ331299A (cg-RX-API-DMAC7.html)
WO (1) WO1997031024A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1143006T3 (da) * 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
JP2002530081A (ja) 1998-11-18 2002-09-17 ジェネンテック・インコーポレーテッド 親抗体より高度な結合親和性を持つ抗体変異体
JP4334866B2 (ja) * 2000-10-09 2009-09-30 アイシス イノヴェイション リミテッド 治療用抗体
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20040109855A1 (en) * 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
KR20060002896A (ko) * 2003-03-31 2006-01-09 기린 비루 가부시키가이샤 항 ｃｄ52 항체에 의한 조절성 ｔ 세포 분화 유도ㆍ증식방법 및 그를 위한 의약 조성물
AU2005246073B2 (en) * 2004-05-19 2010-10-28 Adaptimmune Limited Method of improving T cell receptors
CA2601400A1 (en) * 2005-03-19 2006-09-28 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US20100197896A1 (en) * 2007-05-16 2010-08-05 Leung Shui-On Functional humanization of complementarity determining regions (cdrs)
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
BRPI1006141B8 (pt) 2009-01-12 2021-05-25 Cytomx Therapeutics Llc composições de anticorpo modificado, métodos para preparar e usar as mesmas
CN102481341B (zh) 2009-02-23 2017-05-17 希托马克斯医疗有限公司 蛋白原及其使用方法
KR20140102764A (ko) 2009-05-13 2014-08-22 겐자임 코포레이션 항-인간 ｃｄ52 면역글루불린
AU2010252939B2 (en) 2009-05-29 2014-06-26 Morphosys Ag A collection and methods for its use
US8367586B2 (en) 2010-11-19 2013-02-05 Morphosys Ag Collection and methods for its use
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
WO2013152011A1 (en) * 2012-04-02 2013-10-10 Ab Biosciences, Inc. Novel human control antibodies and uses therefor
AU2013251310B2 (en) 2012-04-27 2018-02-15 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
KR20150139955A (ko) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
US9737623B2 (en) 2013-12-11 2017-08-22 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
US20160120158A1 (en) * 2014-11-03 2016-05-05 The Johns Hopkins University Compositions and methods for the study and treatment of acute kidney injury
TW201717935A (zh) 2015-06-03 2017-06-01 波士頓生醫公司 用於治療癌症的組成物和方法
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
CA3137587A1 (en) 2019-04-30 2020-11-05 Institute For Cancer Research D/B/A/ The Research Institute Of Fox Chase Cancer Center Compositions and methods for modulation of antibody activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0328404B1 (en) * 1988-02-12 1993-09-29 Btg International Limited Modified antibodies
US5846534A (en) 1988-02-12 1998-12-08 British Technology Group Limited Antibodies to the antigen campath-1
US5858725A (en) 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DK0610447T3 (da) * 1991-10-15 1999-08-23 Btg Int Ltd CDw52-specifikt antistof til behandling af T-cellemedieret inflammation af leddene
GB9125768D0 (en) * 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method

Also Published As

Publication number Publication date
JP4574750B2 (ja) 2010-11-04
ES2294793T3 (es) 2008-04-01
DE69738138D1 (de) 2007-10-25
CA2246715A1 (en) 1997-08-28
WO1997031024A1 (en) 1997-08-28
JP2000506723A (ja) 2000-06-06
CA2246715C (en) 2008-08-05
GB9603507D0 (en) 1996-04-17
NZ331299A (en) 2000-05-26
EP0970127A1 (en) 2000-01-12
EP0970127B1 (en) 2007-09-12
US20020048578A1 (en) 2002-04-25
US8440190B2 (en) 2013-05-14
AU723366B2 (en) 2000-08-24
AU1885197A (en) 1997-09-10
US20060018898A1 (en) 2006-01-26
DE69738138T2 (de) 2008-06-05

Similar Documents

Publication Publication Date Title
ATE373016T1 (de) Induktion von immunologischer toleranz gegen einen therapeutischen antikörper durch varianten des therapeutischen antikörpers
DE60230029D1 (de) Immunisierungstherapie zur behandlung von atherosklerose
AT500379B1 (de) Tau-proteine
DE69433406T2 (de) Antikörper gegen cd40
ATE513563T1 (de) Therapeutische und toleranz-induzierende antikörper
ATE470676T1 (de) Anti-vegf-2 antikörper
ATE178907T1 (de) Rezeptorbindende region des diphtherietoxius
ATE414104T1 (de) Fragmente des menschlichen choriogonadotropin (hcg) als immunregulator
CY1109817T1 (el) Ολιγο-βητα-(1,3)-γλυκανη και μονοκλωνικα αντισωματα εναντιον καρκινου
BG101024A (bg) Моноклонално антитяло срещу сd44v6
DE60238533D1 (de) Nicht-depletierender Antikörper TRX-1 gegen CD4 und dessen Verwendungen
DE69530844D1 (de) Verfahren und substanzen gegen protozoen
EP1411962A4 (en) TREATMENT OF PANCREATIC CANCER WITH A MONOCLONAL ANTIBODY
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
PT812206E (pt) Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria
EA200200974A1 (ru) Моноклональные антитела к рецептору лпнп человека, их получение и применение
DE69636527D1 (de) Antigenes protein aus malassezia
ATE136469T1 (de) Neue verwendung eines monoklonalen antikörpers
ATE108832T1 (de) Verwendung von monoklonalen antikörpern gegen b2- mikroglobulin.
DK0858465T3 (da) Protein med antitumorvirkning.
RU96123360A (ru) Способ лечения сепсиса у новорожденных

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties